VENLO, The Netherlands—Qiagen and BioHelix announced they have entered into a non-exclusive worldwide license and supply agreement for BioHelix's proprietary Helicase Dependent Amplification technology (HDA). HDA is a versatile assay technology to detect and analyze biological target molecules such as DNA and RNA by amplifying target specific genetic information with the highest level of sensitivity and specificity. Financial terms were not disclosed. This licensing agreement adds a further amplification technology to Qiagen's broad intellectual property estate of amplification and assay technologies that includes numerous PCR and PCR-similar technologies as well as technologies such as rolling circle amplification (RCA) and whole genome/transcriptome amplification.